AstraZeneca enters a $270m deal with Cheplapharm to divest seven drugs, in order to reduce its portfolio of ‘mature’ medicines and reinvest in other therapeutic areas.
Innovate Pharmaceuticals has launched what it claims is the world’s first shelf-stable liquid aspirin, and says it is on the look-out for a licensing partner for the “$500m” market.
Canadian contract manufacturer Patheon has teamed up with specialty
pharmaceutical firm Depomed to offer its clients a controlled
release formulation which can grant their drugs increased
bioavailability and less frequent dosing.
A new drug delivery company, Merrion Pharmaceuticals, has been set
up to commercialise various technologies originally developed at
Ireland's Elan, which sold off many of its assets after growing too
quickly throughout the 1990s.
UCB has been awarded a US patent on a formulation technology that
could represent a low-cost means of achieving a difficult task -
making a drug that needs to be absorbed in the stomach suitable for
once-daily administration.
